国内外疫苗风险效益评估评价方法进展

doi:10.19803/j.1672-8629.2021.11.22

摘要/Abstract

摘要： 疫苗的风险效益评估方式已经成为监管机构和疫苗企业评价疫苗的重要决策工具,目前国外疫苗风险效益评估方法处于起步阶段,没有统一模式,质量调整生命年法和多准则决策分析法理论及应用较多,世界卫生组织（WHO）制定了医疗产品国家监管体系评估全球基准工具用来评估疫苗国家监管体系,其中包括疫苗的风险效益评估工作相关要求。我国应逐步建立并完善疫苗风险效益评估方法,同时需要监管机构、公共卫生机构、疫苗生产企业共建共享数据平台,提供更多证据,促进疫苗评价工作,完善我国疫苗监管体系。

关键词: 疫苗, 风险效益评估, 质量调整生命年, 多准则决策分析

Abstract: The way in which the risk & benefit of vaccines are assessed has become an important means by which regulators and vaccine manufactures assess vaccines. Currently, foreign methods of assessment of the risk & benefit of vaccines are not yet full-fledged and there are no universally-used ones. The methods of quality-adjusted life years and multi-criteria decision-making method were prevalent. the World Health Organization (WHO) developed the Global Benchmark Tool for the national regulatory system for medical products to assess national regulatory systems for vaccines, including requirements related to the risk & benefit assessment of vaccines. China is to gradually establish and improve methods of assessment of the risk & benefit vaccines. Meanwhile, regulatory authorities, public health institutions and vaccine manufacturers should build a shared data platform to provide more evidence, promote vaccine assessment and improve China's vaccine regulatory systems.

Key words: vaccines, risk benefit assessment, quality-adjusted life year, multi-criteria decision-making

中图分类号:

R186

刘春光, 梁龚山, 许长青. 国内外疫苗风险效益评估评价方法进展[J]. 中国药物警戒, 2021, 18(11): 1097-1100.

LIU Chunguang, LIANG Gongshan, XU Changqing. Research Progress in Methods of Risk & Benefit Assessment of Vaccines[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1097-1100.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.2021.11.22

https://zgywjj.magtechjournal.com/CN/Y2021/V18/I11/1097

参考文献

[1] WHO. Immunization[EB/OL].(2020-03-13)[2020-07-16]. https://www.who.int/topics/immunization/en/.
[2] Chen RT, Glanz JM, Vellozzi C.Pharmacoepidemiologic studies of vaccine safety[J]. Pharmacoepidemiology, 2012, 5(1):423-468.
[3] European Medicines Agency. Guideline on good pharmacovigilance practices. Vaccines for prophylaxis against infectious diseases[EB/OL].(2013-05-10)[2020-10-16].https://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/12/WC500157839.pdf.
[4] Schosser R.Risk/benefit evaluation of drugs: The role of the pharmaceutical industry in Germany[J]. Eur Surg Res, 2002, 34(1-2):203-205.
[5] Mt-Isa S, Hallgreen CE, Wang N, et al.Balancing benefit and risk of medicines: a systematic review and classification of available methodologies[J]. Pharmacoepidemiol Drug Saf, 2014. 23(7): 667-678.
[6] Pitman R, Fisman D, Zaric GS, et al.Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5[J]. Value Health, 2012,15(6): 828-834.
[7] Zhou N, Xu HM.Research progress (onf BCG)) in children[J]. Journal of Pediatric Pharmacy, 2021, 27(3): 34-36.
[8] Clark M, Cameron DW.The benefits and risks of bacille Calmette-Guerin vaccination among infants at high risk for both tuberculosis and severe combined immunodeficiency: assessment by Markov model[J]. BMC Pediatr, 2006, 6: 5.
[9] Claxton K, Paulden M, Gravelle H, et al.Discounting and decision making in the economic evaluation of health-care technologies[J]. Health Econ, 2011, 20(1): 2-15.
[10] Goyal R.BCG vaccination in BCG scar negative children[J]. Indian Pediatrics, 1998, 6(32): 67.
[11] Brisson M, Van de Velde N, Boily MC. Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11[J].Sex Transm Infect, 2011, 87(1): 4143.
[12] Tang M, Yang Y, Hu SL.Theoretical basis and progress of multi-criteria decision analysis in healthcare decision-making[J]. Chinese Health Resources,2020,23(4):325-331.
[13] EMA. Launch of European project for monitoring benefits and risks of vaccines throughout their lifecycle[EB/OL].(2013-11-26)[2020-10-19]. https://www.ema.europa.eu/en/news/launch-european-project-monitoring-benefits-risks-vaccines-throughout-their-lifecycle.
[14] IMI mission and objectives Europe's partnership for health[EB/OL]. (2020-03-31) [2020-11-10]. https://www.imi.europa.eu/.
[15] Key organisations unite to improve benefit & risk assessments of vaccines ADVANCE project factsheet[EB/OL]. (2013-11-26) [2021-02-10]. https://www.imi.europa.eu/news-events/press-releases/key-organisations-unite-improve-benefit-risk-assessments-vaccines.
[16] WHO. List of vaccine producing countries with functional NRAs [EB/OL]. (2016-12-26) [2021-03-10]. https://www.who.int/initiatives/who-listed-authority-reg-authorities/list-of-vaccine-prod-countries.
[17] Gong L, Pan LY, Liu Y.Detection and evaluation of post-marketing safety alert signals for human papillomavirus 9-valent vaccine based on US vaccine adverse event reporting system (VAERS)[J]. Chinese Journal of Pharmacovigilance, 2019, 16(8): 478-488.
[18] Accelerated development of vaccine benefit-risk collaboration in Europe [EB/OL].(2019-03-31)[2020-11-10]. https://www.imi.europa.eu/projects-results/project-factsheets/advance.
[19] Pearce A, Marshall H, Bedford H, et al.Barriers to childhood immunisation: findings from the longitudinal study of australian children[J]. Vaccine, 2015, 33(29): 3377-3383
[20] Ruderfer D, Krilov LR.Vaccine-preventable outbreaks: still with us after all these years[J]. Pediatr Ann, 2015, 44(4): 76-81
[21] Weinstein MC, Siege JE, Gold MR, et al.Recommendations of the panel on cost-effectiveness in health and medicine[J].JAMA,1996,12(4):1253-1258.
[22] Jit M, Mibei W.Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review[J].Vaccine, 2015, 33(32): 3788-3794.